Helmholtz Gemeinschaft


Novel baroreflex activation therapy in resistant hypertension results of a European multi-center feasibility study

Item Type:Article
Title:Novel baroreflex activation therapy in resistant hypertension results of a European multi-center feasibility study
Creators Name:Scheffers, I.J. and Kroon, A.A. and Schmidli, J. and Jordan, J. and Tordoir, J.J. and Mohaupt, M.G. and Luft, F.C. and Haller, H. and Menne, J. and Engeli, S. and Ceral, J. and Eckert, S. and Erglis, A. and Narkiewicz, K. and Philipp, T. and de Leeuw, P.W.
Abstract:OBJECTIVES: This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. BACKGROUND: Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. METHODS: Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An external programmer was used to optimize and individualize efficacy. RESULTS: Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. CONCLUSIONS: The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
Keywords:Baroreflex, Device, Feasibility, Hypertension, Treatment
Source:Journal of the American College of Cardiology
Page Range:1254-1258
Date:5 October 2010
Official Publication:https://doi.org/10.1016/j.jacc.2010.03.089
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library